HSBC

$81.07+0.17 (+0.21%)

Market OpenAs of Mar 18, 1:50 PM UTC

HSBC Holdings plc engages in the provision of banking and financial products and services worldwide.

Recent News

Insider Monkey
Mar 18, 2026

Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why

Eli Lilly and Company (NYSE:LLY) is one of the best ethical companies to invest in now according to Reddit. Eli Lilly and Company (NYSE:LLY) was downgraded to Reduce from Hold by HSBC on March 17, with the firm bringing the price target on the stock down to $850 from $1,070. The firm told investors in […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 18, 2026

HSBC Raises Its Price Target on YPF Sociedad Anonima (YPF) As Analyst Turn Bullish On The Stock

YPF Sociedad Anónima (NYSE:YPF) is one of the 8 most undervalued oil stocks to buy. Lilyanna Yang from HSBC increased the firm’s price target on YPF Sociedad Anónima (NYSE:YPF) from $36 to $40 while reiterating a Hold rating on March 12. According to the firm, the price target revision reflects its updated outlook for oil […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Yahoo Finance UK
Mar 18, 2026

Best credit card deals of the week

Discover the best credit cards to save money, earn rewards and travel smarter

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 18, 2026

Why Eli Lilly (LLY) Shares Are Plunging Today

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stock to a sell-equivalent "reduce" rating from "hold," citing concerns that its shares were "priced to perfection."

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TheStreet
Mar 18, 2026

HSBC drops blunt verdict on 150-year-old dividend stock

Eli Lilly has spent the last decade transforming from a reliable but unremarkable dividend payer into one of the most talked-about stocks on Wall Street. Its obesity and diabetes franchise, built around tirzepatide, the active ingredient in both Zepbound and Mounjaro, has sent the dividend stock ...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.